Skip to main content
SpringerLink
Log in

New Therapeutic Approaches in Signaling

  • Chapter
  • First Online:
Melanoma Development

  • 886 Accesses

Abstract

The emergence of selective BRAF inhibitors for the treatment of metastatic melanoma appears poised to change the therapeutic landscape in this disease. For decades the melanoma field has lagged behind others in achieving significant alteration in the natural history of metastatic disease with conventional cytotoxic chemotherapy. Even immunotherapy, a treatment standard both in the metastatic and adjuvant setting, fails to benefit more than a small minority of patients. While recent clinical trial results featuring novel immunologic therapies appear to be breaking the barriers observed with the previous generation of cytokine-based immunotherapies, the treatment of metastatic melanoma remains a severely unmet need. It is hoped that the discovery of somatic genetic alterations in signal transduction pathways that regulate proliferation, cell cycle, differentiation, and survival will provide further opportunities for expanding the reach of targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Albino AP, Le Strange R, Oliff AI, Furth ME, Old LJ (1984) Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 308:69–72

    Article  PubMed  CAS  Google Scholar 

  • Altomare DA, Lyons GE, Mitsuuchi Y, Cheng JQ, Testa JR (1998) Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene 16:2407–2411

    Article  PubMed  CAS  Google Scholar 

  • Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116

    PubMed  CAS  Google Scholar 

  • Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D’andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, Mcarthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596–599

    Article  PubMed  CAS  Google Scholar 

  • Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213–5219

    Article  PubMed  CAS  Google Scholar 

  • Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439–444

    Article  PubMed  CAS  Google Scholar 

  • Carvajal R, Chapman PB, Wolchok JD, Cane L, Teitcher JB, Lutzky J, Pavlick AC, Bastian BC, Antonescu CR, Schwartz GK (2009) A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 27:9001

    Google Scholar 

  • Celebi JT, Shendrik I, Silvers DN, Peacocke M (2000) Identification of PTEN mutations in metastatic melanoma specimens. J Med Genet 37:653–657

    Article  PubMed  CAS  Google Scholar 

  • Corominas M, Kamino H, Leon J, Pellicer A (1989) Oncogene activation in human benign tumors of the skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation? Proc Natl Acad Sci USA 86:6372–6376

    Article  PubMed  CAS  Google Scholar 

  • Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G (2005) Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol 175:820–828

    PubMed  CAS  Google Scholar 

  • Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, Leboit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147

    Article  PubMed  CAS  Google Scholar 

  • Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340–4346

    Article  PubMed  CAS  Google Scholar 

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954

    Article  PubMed  CAS  Google Scholar 

  • Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB (2008) A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99:1265–1268

    Article  PubMed  CAS  Google Scholar 

  • De Laurentiis A, Pardo OE, Palamidessi A, Jackson SP, Schoenwaelder SM, Reichmann E, Scita G, Arcaro A (2011) The catalytic class I(A) PI3K Isoforms play divergent roles in breast cancer cell migration. Cell Signal 23:529–541

    Article  PubMed  Google Scholar 

  • Demetri GD, Von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480

    Article  PubMed  CAS  Google Scholar 

  • Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, Mcarthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  PubMed  CAS  Google Scholar 

  • Dhomen N, Reis-Filho JS, Da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15:294–303

    Article  PubMed  CAS  Google Scholar 

  • Eskandarpour M, Huang F, Reeves KA, Clark E, Hansson J (2009) Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Int J Cancer 124:16–26

    Article  PubMed  CAS  Google Scholar 

  • Flaherty KT, Redlinger M, Schuchter LM, Lathia CD, Weber BL, O’dwyer PJ (2005) Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. J Clin Oncol 23:3037

    Google Scholar 

  • Flaherty KT, Puzanov I, Kim KB, Ribas A, Mcarthur GA, Sosman JA, O’dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanom. N Engl J Med 363:809–819

    Article  PubMed  CAS  Google Scholar 

  • Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427–1438

    PubMed  CAS  Google Scholar 

  • Fujimoto A, Morita R, Hatta N, Takehara K, Takata M (1999) p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 18:2527–2532

    Article  PubMed  CAS  Google Scholar 

  • Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, Ushijima T (2004) Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 95:962–968

    Article  PubMed  CAS  Google Scholar 

  • Gajewski TK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich M, Sebti S, Haluska F (2006) Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104. J Clin Oncol 24:8014

    Google Scholar 

  • Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR (2005) Integrative genomic analyses identify MITF as a lineage ­survival oncogene amplified in malignant melanoma. Nature 436:117–122

    Article  PubMed  CAS  Google Scholar 

  • Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, Rodenburg RJ, Smeitink JA, Oberley L, Zhang Y, Slingerland J, Arnold RS, Lambeth JD, Cohen C, Hilenski L, Griendling K, Martinez-Diez M, Cuezva JM, Arbiser JL (2007) Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117:719–729

    Article  PubMed  CAS  Google Scholar 

  • Guldberg P, Thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57:3660–3663

    PubMed  CAS  Google Scholar 

  • Guo J, Si L, Kong Y, Xu X, Flaherty KT, Corless CL, Zhu YY, Li L, Li HF (2010) A phase II study of imatinib for advanced melanoma patients with KIT aberrations. J Clin Oncol 28:15s

    Article  Google Scholar 

  • Haferkamp S, Becker TM, Scurr LL, Kefford RF, Rizos H (2008) p16INK4a-induced senescence is disabled by melanoma-associated mutations. Aging Cell 7:733–745

    Article  PubMed  CAS  Google Scholar 

  • Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410–1413

    Article  PubMed  CAS  Google Scholar 

  • Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O’day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823–2830

    Article  PubMed  CAS  Google Scholar 

  • Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209–221

    Article  PubMed  CAS  Google Scholar 

  • Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63:5198–5202

    PubMed  CAS  Google Scholar 

  • Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van Den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046–2051

    Article  PubMed  CAS  Google Scholar 

  • Hodi FS, O’day SJ, Mcdermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, Van Den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  PubMed  CAS  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  • Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nat Genet 8:15–21

    Article  PubMed  CAS  Google Scholar 

  • Infante JR, Fecher LA, Nallapareddy S, Gordon MS, Flaherty KT, Cox DS, Demarini DJ, Morris SR, Burris HA, Messersmith WA (2010) Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 28:15s

    Google Scholar 

  • Jain RK, Tong RT, Munn LL (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67:2729–2735

    Article  PubMed  CAS  Google Scholar 

  • Janas ML, Hodson D, Stamataki Z, Hill S, Welch K, Gambardella L, Trotman LC, Pandolfi PP, Vigorito E, Turner M (2008) The effect of deleting p110delta on the phenotype and function of PTEN-deficient B cells. J Immunol 180:739–746

    PubMed  CAS  Google Scholar 

  • Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchook GS, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchook GS (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28:15s

    Google Scholar 

  • Kim KB, Eton O, Davis DW, Frazier ML, Mcconkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG (2008) Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99:734–740

    Article  PubMed  CAS  Google Scholar 

  • King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KS, Herlyn M, Morrissey MM, Tuveson DA, Huang PS (2006) Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 66:11100–11105

    Article  PubMed  CAS  Google Scholar 

  • Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166

    PubMed  CAS  Google Scholar 

  • Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  PubMed  CAS  Google Scholar 

  • Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, Hengge UR (2006) Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 66:6546–6552

    Article  PubMed  CAS  Google Scholar 

  • Mishra PJ, Ha L, Rieker J, Sviderskaya EV, Bennett DC, Oberst MD, Kelly K, Merlino G (2010) Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene 29:2449–2456

    Article  PubMed  CAS  Google Scholar 

  • Mordant P, Loriot Y, Leteur C, Calderaro J, Bourhis J, Wislez M, Soria JC, Deutsch E (2010) Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther 9:358–368

    Article  PubMed  CAS  Google Scholar 

  • Muthusamy V, Hobbs C, Nogueira C, Cordon-Cardo C, Mckee PH, Chin L, Bosenberg MW (2006) Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosom Cancer 45:447–454

    Article  PubMed  CAS  Google Scholar 

  • Nogueira C, Kim KH, Sung H, Paraiso KH, Dannenberg JH, Bosenberg M, Chin L, Kim M (2010) Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29:6222–6232

    Article  PubMed  CAS  Google Scholar 

  • O’dwyer PJ, LoRusso P, Demichele A, Gupta V, Barbi A, Dials H, Chen I, Courtney R, Wilner K, Schwartz GK (2007) A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991. J Clin Oncol 25:18s

    Google Scholar 

  • Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS (2010) Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 102:1724–1730

    Article  PubMed  CAS  Google Scholar 

  • Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427–430

    Article  PubMed  CAS  Google Scholar 

  • Robinson JP, Vanbrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL (2010) Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene 29:335–344

    Article  PubMed  CAS  Google Scholar 

  • Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris DA, Shellman YG (2006) RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. J Invest Dermatol 126:862–868

    Article  PubMed  CAS  Google Scholar 

  • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  PubMed  CAS  Google Scholar 

  • Scheuermann JC, De Ayala Alonso AG, Oktaba K, Ly-Hartig N, Mcginty RK, Fraterman S, Wilm M, Muir TW, Muller J (2010) Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465:243–247

    Article  PubMed  CAS  Google Scholar 

  • Sebti SM, Hamilton AD (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19:6584–6593

    Article  PubMed  CAS  Google Scholar 

  • Shao Y, Aplin AE (2010) Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70:6670–6681

    Article  PubMed  CAS  Google Scholar 

  • Smalley KS, Eisen TG (2003) Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer 105:165–175

    Article  PubMed  CAS  Google Scholar 

  • Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP (2004) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:7002–7010

    Article  PubMed  CAS  Google Scholar 

  • Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Mumm JB, Zumstein L, Watson GJ, Snary D, Roth JA, Grimm EA, Ramesh R, Chada S (2002) PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med 8:451–461

    PubMed  CAS  Google Scholar 

  • Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122:337–341

    Article  PubMed  CAS  Google Scholar 

  • Tsukamoto H, Irie A, Senju S, Hatzopoulos AK, Wojnowski L, Nishimura Y (2008) B-Raf-mediated signaling pathway regulates T cell development. Eur J Immunol 38:518–527

    Article  PubMed  CAS  Google Scholar 

  • Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A, Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, Schadendorf D (2005) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92:1398–1405

    Article  PubMed  CAS  Google Scholar 

  • Van Gils W, Lodder EM, Mensink HW, Kilic E, Naus NC, Bruggenwirth HT, Van Ijcken W, Paridaens D, Luyten GP, De Klein A (2008) Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis. Invest Ophthalmol Vis Sci 49:4254–4262

    Article  PubMed  Google Scholar 

  • Van Raamsdonk CD, Fitch KR, Fuchs H, De Angelis MH, Barsh GS (2004) Effects of G-protein mutations on skin color. Nat Genet 36:961–968

    Article  PubMed  Google Scholar 

  • Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’brien JM, Simpson EM, Barsh GS, Bastian BC (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599–602

    Article  PubMed  Google Scholar 

  • Venetsanakos E, Stuart D, Tan N, Ye H, Salangsang F, Aardalen K, Faure M, Heise C, Mendel D, Jallal B (2006) CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models. In: 97th Proceedings or the American Association Cancer Research annual meeting, Washington DC, 2006, p 47

    Google Scholar 

  • Wagner SN, Wagner C, Briedigkeit L, Goos M (1998) Homozygous deletion of the p16INK4a and the p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. Br J Dermatol 138:13–21

    Article  PubMed  CAS  Google Scholar 

  • Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, Marais R (2004) V599EB-RAF is an oncogene in melanocytes. Cancer Res 64:2338–2342

    Article  PubMed  CAS  Google Scholar 

  • Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, Marais R (2010) Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med 2:35ra41

    Article  PubMed  Google Scholar 

  • Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, Koo HM, Holmen SL (2007) Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene 26:4563–4570

    Article  PubMed  CAS  Google Scholar 

  • Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835–844

    Article  PubMed  CAS  Google Scholar 

  • Wyman K, Atkins MB, Prieto V, Eton O, Mcdermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA (2006) Multicenter phase II trial of high-dose imatinib mesylate in metastatic ­melanoma: significant toxicity with no clinical efficacy. Cancer 106:2005–2011

    Article  PubMed  CAS  Google Scholar 

  • Yan L (2009) MK-2206: a potent oral allosteric AKT inhibitor. In: Proceedings of the American Association for Cancer Research, Denver, 2009, DDT01-1

    Google Scholar 

  • Yokoyama S, Feige E, Poling LL, Levy C, Widlund HR, Khaled M, Kung AL, Fisher DE (2008) Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21:457–463

    Article  PubMed  CAS  Google Scholar 

  • Zhang S, Yu D (2010) PI(3)king apart PTEN’s role in cancer. Clin Cancer Res 16:4325–4330

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Developmental Therapeutics, Harvard School of Medicine, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA, 02114, USA

    Keith T. Flaherty

Authors
  1. Keith T. Flaherty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keith T. Flaherty .

Editor information

Editors and Affiliations

  1. , Molecular Pathology, Institute of Pathololgy, Franz-Josef-Strauss-Allee 11, Regensburg, 93053, Germany

    Anja Bosserhoff

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag/Wien

About this chapter

Cite this chapter

Flaherty, K.T. (2011). New Therapeutic Approaches in Signaling. In: Bosserhoff, A. (eds) Melanoma Development. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0371-5_16

Download citation

Publish with us

Policies and ethics

Search

Navigation